Smallpox - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 89 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Smallpox - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Smallpox - Pipeline Review, H2 2014', provides an overview of the Smallpox's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Smallpox
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Smallpox and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Smallpox products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Smallpox pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Smallpox
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Smallpox pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Smallpox Overview 8
Therapeutics Development 9
Pipeline Products for Smallpox - Overview 9
Pipeline Products for Smallpox - Comparative Analysis 10
Smallpox - Therapeutics under Development by Companies 11
Smallpox - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Smallpox - Products under Development by Companies 17
Smallpox - Companies Involved in Therapeutics Development 18
Inovio Pharmaceuticals, Inc. 18
Bavarian Nordic A/S 19
Symphogen A/S 20
Nanotherapeutics, Inc. 21
CEL-SCI Corporation 22
SIGA Technologies, Inc. 23
TapImmune Inc. 24
CJ CheilJedang Corp. 25
MacroGenics, Inc. 26
AlphaVax, Inc. 27
EpiVax, Inc. 28
Chimerix, Inc. 29
Conkwest, Inc. 30
Inhibikase Therapeutics, Inc. 31
Polyrizon Ltd. 32
Smallpox - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 43
smallpox vaccine [Modified Vaccinia Ankara - Bavarian Nordic Virus] - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CJ-50300 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
brincidofovir - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Sym-002 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
cidofovir - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
CEL-1000 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
tecovirimat - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
DNA Vaccine for Smallpox - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Smallpox Vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
CST-102 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
DNA Vaccine for Smallpox - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
TPIV-300 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
imatinib mesylate - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Monoclonal Antibody for Infectious Disease - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
PL-801 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Smallpox Vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Smallpox - Recent Pipeline Updates 65
Smallpox - Dormant Projects 78
Smallpox - Discontinued Products 79
Smallpox - Product Development Milestones 80
Featured News & Press Releases 80
Apr 22, 2014: Bavarian Nordic Announces Execution of Option on Freeze-Dried IMVAMUNE 80
Nov 22, 2013: Bavarian Nordic Receives Health Canada Approval of IMVAMUNE Smallpox Vaccine 80
Nov 15, 2013: Bavarian Nordic Completes Delivery of 20 Million Doses of IMVAMUNE Smallpox Vaccine to the U.S. Strategic National Stockpile 81
Aug 07, 2013: Bavarian Nordic Receives European Marketing Authorization for IMVANEX Smallpox Vaccine 82
Jun 03, 2013: Chimerix And BARDA Continue Collaboration On Development Of CMX001 As Medical Countermeasure Against Smallpox 83
May 31, 2013: Bavarian Nordic's Imvanex Vaccine Receives Positive CHMP Opinion For Active Immunization Against Smallpox 84
May 29, 2013: SIGA Completes Second Delivery Of Arestvyr Under BARDA Contract 84
May 26, 2013: PharmAthene Announces Delaware Supreme Court Upholds Lower Court Ruling In Lawsuit Against SIGA Technologies 85
May 16, 2013: Chimerix Presents Data On CMX001 At 26th International Conference On Antiviral Research 85
Apr 16, 2013: Bavarian Nordic Receives Contract Valued Up To $228m From BARDA Securing Continued Production And Deliveries Of Imvamune Smallpox Vaccine 86
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 89
Disclaimer 89

List of Tables
Number of Products under Development for Smallpox, H2 2014 9
Number of Products under Development for Smallpox - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Comparative Analysis by Unknown Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Smallpox - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 18
Smallpox - Pipeline by Bavarian Nordic A/S, H2 2014 19
Smallpox - Pipeline by Symphogen A/S, H2 2014 20
Smallpox - Pipeline by Nanotherapeutics, Inc., H2 2014 21
Smallpox - Pipeline by CEL-SCI Corporation, H2 2014 22
Smallpox - Pipeline by SIGA Technologies, Inc., H2 2014 23
Smallpox - Pipeline by TapImmune Inc., H2 2014 24
Smallpox - Pipeline by CJ CheilJedang Corp., H2 2014 25
Smallpox - Pipeline by MacroGenics, Inc., H2 2014 26
Smallpox - Pipeline by AlphaVax, Inc., H2 2014 27
Smallpox - Pipeline by EpiVax, Inc., H2 2014 28
Smallpox - Pipeline by Chimerix, Inc., H2 2014 29
Smallpox - Pipeline by Conkwest, Inc., H2 2014 30
Smallpox - Pipeline by Inhibikase Therapeutics, Inc., H2 2014 31
Smallpox - Pipeline by Polyrizon Ltd., H2 2014 32
Assessment by Monotherapy Products, H2 2014 33
Number of Products by Stage and Target, H2 2014 35
Number of Products by Stage and Mechanism of Action, H2 2014 37
Number of Products by Stage and Route of Administration, H2 2014 39
Number of Products by Stage and Molecule Type, H2 2014 42
Smallpox Therapeutics - Recent Pipeline Updates, H2 2014 65
Smallpox - Dormant Projects, H2 2014 78
Smallpox - Discontinued Products, H2 2014 79